13th Miltenyi Biotec Scientific Days Paris

Mobilizing specific T cells against cancer

Friday, July 5, 2019
08:30 a.m.—05:00 p.m.
Cité Internationale Universitaire de Paris
17 Boulevard Jourdan, 75014, Paris

Agenda

08:30 a.m.	Introduction and opening Guido Kroemer, Centre de Recherche des Cordeliers, France Laurence Zitvogel, Institut Gustave Roussy, France
08:45 a.m.	Agonism T cells through ICOS agonist antibodies Axel Hoos, GlaxoSmithKline, USA
09:30 a.m.	Stem-like qualities of anti-tumor immune responses upon adoptive transfer Enrico Lugli, Humanitas Clinical and Research Center, Italy
10:00 a.m.	Using automation and innovation to fuel advanced T cell therapies Andrew Kaiser, Miltenyi Biotec, Germany
10:30 a.m.	Coffee break
11:00 a.m.	Precision engineering to advance adoptive T cell therapies Justin Eyquem, University of California, San Francisco, USA
11:30 a.m.	Epigenetic control of tumor infiltrating T cells Sebastian Amigorena, Institut Curie, France
12:00 p.m.	Lunch break
02:00 p.m.	Use of bispecific antibodies to enable adoptive T cell therapy of cancer Sebastian Kobold, Klinikum der Universität München, Germany
02:30 p.m.	Safe redirection of T lymphocytes against HER2-positive tumors Joaquin Arribas, Vall d’Hebron Institute of Oncology, Spain
03:00 p.m.	Engineered bispecific antibodies for combination cancer immunotherapy Christian Klein, Roche Innovation Center, Switzerland
03:30 p.m.	Coffee break
04:00 p.m.	Arming the prime time killer: an immune engineering perspective Jogender Tushir-Singh, University of Virginia, USA
04:30 p.m.	Development of novel fully human bispecific antibodies for oncology Dimitris Skokos, Regeneron Pharmaceuticals, USA